Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib (CA-4948) in AML or hrMDS
NCT04278768Phase 2Suspended
- Sponsor
- Curis, Inc.
- Start
- Jul 2020
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of emavusertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Curis, Inc.. Started Jul 2020; status: suspended.
02
Drugs
emavusertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04278768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278768.